Among the patients with EGFR mutations, shorter progression-free survival (PFS) was observed in SCC compared to adenocarcinoma (4.6 vs. 11.0 months, P<0.001)…Further exploration of EGFR-mutant SCC revealed that mutations in CREBBP (P=0.005), ZNF217 (P=0.016), and the Wnt (P=0.027) pathway were negatively associated with PFS....Mutations in other genes, such as CREBBP, ZNF217, GRM8 or Wnt that had implications on PFS raise the possibility of understanding mechanisms of resistance to EGFR-TKI in lung SCC...